89Bio Investor Relations Material
Latest events
Status Update
89Bio
Q2 2025
7 Aug, 2025
Q1 2025
1 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from 89Bio Inc
Access all reports
89Bio Inc is a clinical-stage biopharmaceutical company focused to the development and commercialization of therapies aimed at treating liver and cardio-metabolic diseases. The company is building a pipeline that includes biologic and small molecule treatments, focusing on addressing unmet medical needs in these therapeutic areas. The company is headquartered in San Francisco, California, and its shares are listed on the NASDAQ under the symbol ETNB.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
ETNB
Country
🇺🇸 United States